Zimmer Biomet Holdings, Inc. (ZBH) Stock Price

ZBHStock

$100.91−3.95%52W

Market Cap$19.25B

P/E26.44x

PEG Ratio0.67

Div yield1.04%

Beta0.48

ZBH Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-10.89%

Price vs S&P 500 (4W)2.51%

PEG Ratio0.67

VGM Score61.82

P/E Ratio (Annual)26.44x

Indicated Dividend Yield (Annual)1.04%

P/CF (Annual)10.99x

Book Value / Share (Quarterly)$66.23

P/TBV (Annual)2.23x

Indicated Dividend (Annual)$0.96

Revenue Growth (3Y)5.85%

Cash Flow / Share (Quarterly)$5.66

Payout Ratio (TTM)23.37%

Price vs S&P 500 (YTD)-0.60%

Gross Margin (TTM)69.87%

Net Profit Margin (TTM)9.48%

EPS (TTM)$4.11

10-Day Avg Trading Volume1.36M

EPS Excl Extra (TTM)$4.11

Revenue Growth (5Y)3.22%

EPS (Annual)$3.55

Dividend / Share (Annual)$0.96

ROI (Annual)3.49%

Gross Margin (Annual)69.71%

Net Profit Margin (5Y Avg)8.68%

Cash / Share (Quarterly)$2.15

P/E Basic Excl Extra (TTM)23.12x

Revenue Growth QoQ (YoY)4.80%

P/E Normalized (Annual)26.44x

ROA (Last FY)3.05%

Revenue Growth TTM (YoY)8.62%

EBITD / Share (TTM)$9.60

ROE (5Y Avg)5.22%

Operating Margin (TTM)14.16%

Cash Flow / Share (Annual)$5.73

P/B Ratio1.48x

P/B Ratio (Quarterly)1.32x

Net Income / Employee (Annual)$41,500

EV / Revenue (TTM)3.02x

Net Interest Coverage (TTM)3.84x

ROA (TTM)3.50%

EPS Growth QoQ (YoY)33.48%

EV / EBITDA (TTM)13.64x

EPS Incl Extra (Annual)$3.55

Current Ratio (Annual)1.98x

Quick Ratio (Quarterly)0.72x

3-Month Avg Trading Volume2.39M

52-Week Price Return-3.95%

EV / Free Cash Flow (Annual)22.96x

P/E Incl Extra (TTM)23.12x

Revenue / Employee (TTM)$500,500

Tangible BV / Share (Quarterly)$42.82

P/S Ratio (Annual)2.26x

Asset Turnover (Annual)0.36x

52-Week High$106.88

Operating Margin (5Y Avg)13.51%

EPS Excl Extra (Annual)$3.55

CapEx CAGR (5Y)7.11%

Tangible BV CAGR (5Y)9.21%

26-Week Price Return1.04%

Quick Ratio (Annual)0.89x

13-Week Price Return21.84%

Total Debt / Equity (Annual)0.59x

Current Ratio (Quarterly)1.69x

Enterprise Value$25.71B

Revenue / Share Growth (5Y)4.07%

Asset Turnover (TTM)0.37x

Book Value / Share Growth (5Y)2.07%

Revenue / Employee (Annual)$484,200

Inventory Turnover (Annual)1.10x

Pretax Margin (Annual)10.09%

Cash / Share (Annual)$3.03

3-Month Return Std Dev31.18%

Gross Margin (5Y Avg)71.04%

Net Income / Employee (TTM)$47,400

EBITDA CAGR (5Y)28.18%

EBITDA Interim CAGR (5Y)6.47%

ROE (Last FY)5.55%

Net Interest Coverage (Annual)4.23x

EPS Basic Excl Extra (Annual)$3.55

P/FCF (TTM)17.28x

Receivables Turnover (TTM)5.03x

EV / Free Cash Flow (TTM)23.83x

Total Debt / Equity (Quarterly)0.59x

EPS Incl Extra (TTM)$4.11

Receivables Turnover (Annual)5.17x

ROI (TTM)3.97%

Dividend Growth Rate (5Y)0.12%

P/S Ratio (TTM)2.19x

Pretax Margin (5Y Avg)10.23%

Revenue / Share (Annual)$41.43

Tangible BV / Share (Annual)$40.82

Forward P/E10.82x

Free OCF CAGR (5Y)7.09%

Price vs S&P 500 (52W)-22.51%

P/E Ratio (TTM)23.12x

EPS Growth TTM (YoY)0.09%

Year-to-Date Return12.22%

5-Day Price Return-0.07%

EPS Normalized (Annual)$3.55

ROA (5Y Avg)2.97%

Net Profit Margin (Annual)8.57%

Month-to-Date Return7.43%

Cash Flow / Share (TTM)$6.73

EBITD / Share (Annual)$8.88

EPS Growth (3Y)47.75%

Operating Margin (Annual)13.34%

LT Debt / Equity (Annual)0.55x

P/CF (TTM)10.70x

ROI (5Y Avg)3.46%

P/E Excl Extra (TTM)23.12x

LT Debt / Equity (Quarterly)0.50x

EPS Basic Excl Extra (TTM)$4.11

P/TBV (Quarterly)2.04x

Payout Ratio (Annual)26.99%

P/B Ratio (Annual)1.40x

Dividend / Share (TTM)$0.97

Inventory Turnover (TTM)1.09x

Pretax Margin (TTM)10.97%

Book Value / Share (Annual)$64.95

Price vs S&P 500 (13W)19.89%

Dividend Yield (TTM)1.01%

Beta0.48x

P/FCF (Annual)16.65x

Revenue / Share (TTM)$44.13

ROE (TTM)6.35%

52-Week Low$79.12

vGradeB

gGradeC

mGradeB

vgmGradeB

ZBH Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 5, 2026	$2.01	$2.07	+2.99%(+$0.06)
Q1 2026	Apr 28, 2026	$1.86	$2.09	+12.21%(+$0.23)
Q4 2025	Feb 10, 2026	$2.40	$2.42	+0.93%(+$0.02)
Q3 2025	Nov 5, 2025	$1.87	$1.90	+1.83%(+$0.03)
Q2 2025	Aug 7, 2025	$1.98	$2.07	+4.75%(+$0.09)

ZBH Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

3.31

3.41

3.42

Industry Peers — Orthopedic & Prosthetic Devices(33)

Symbol	Value Score	Growth Score	Momentum Score	Price
ZBHZimmer Biomet Holdings, Inc.	B	C	B	$100.91
ISRGIntuitive Surgical Inc.	D	B	C	$372.60
EWEdwards Lifesciences Corp	D	C	B	$90.21
STESTERIS plc	C	B	C	$233.78
SNNSmith & Nephew plc	B	C	C	$28.97
ALGNAlign Technology Inc	B	D	C	$157.58
MSAMine Safety Incorporated	C	C	B	$190.34
ESTAEstablishment Labs Holdings Inc.	F	A	C	$70.64
ENOVEnovis Corporation	B	D	C	$24.90
CDRECadre Holdings, Inc.	C	C	C	$30.74
AVNSAvanos Medical, Inc.	B	D	C	$24.99
AVRAnteris Technologies Global Corp. Common Stock	F	D	B	$8.74
SMTISanara MedTech Inc. Common Stock	D	C	B	$34.57
CNXUConexeu Sciences Inc. Common Stock	—	—	F	$7.07
ZJYLJIN MEDICAL INTERNATIONAL LTD. Class A Ordinary Shares	B	D	D	$2.34
INGNInogen Inc	B	D	C	$5.50
LAKELakeland Industries Inc	B	D	B	$11.86
SPAISafe Pro Group Inc. Common Stock	F	C	D	$4.63
MYOMyomo Inc.	C	B	A	$1.60
APTAlpha Pro Tech, Ltd.	A	D	C	$5.35
NTRBNutriband Inc. Common Stock	F	D	C	$4.46
COCHEnvoy Medical, Inc. Class A Common Stock	D	D	D	$0.69
MLSSMilestone Scientific, Inc. Common Stock	D	D	B	$0.50
LFWDLifeward Ltd. Ordinary Shares	B	D	B	$7.46
RGNTRegentis Biomaterials Ltd.	—	—	D	$2.00
HSCSHeartSciences Inc. Common Stock	F	F	B	$3.03
CUPRCuprina Holdings (Cayman) Limited Class A Ordinary Shares	—	D	C	$3.01
CLGNCollPlant Biotechnologies Ltd Ordinary Shares	C	F	D	$0.36
FEEDENvue Medical, Inc. Common Stock	A	F	F	$0.34
BBLGBone Biologics Corp Common Stock	—	—	D	$0.61
BBLGWBone Biologics Corp Warrants	—	—	F	$5.70
COCHWEnvoy Medical, Inc Warrant	—	—	C	$0.04
HSCSWHeartSciences Inc. Warrant	—	—	D	$0.04
NTRBWNutriband Inc. Warrant	—	—	D	$0.45

About Zimmer Biomet Holdings, Inc.

Zimmer Biomet is a leading designer and manufacturer of orthopedic reconstructive implants and surgical equipment, with dominant market positions in the United States, Europe, and Japan. The company derives approximately two-thirds of revenue from large joint reconstructions, with the remainder from trauma, sports medicine, and extremities products. In 2022, Zimmer spun out its dental and spine businesses to focus on orthopedic reconstruction.